Tested Applications
| Positive IF/ICC detected in | mouse splenocytes |
| Positive FC detected in | mouse splenocytes |
Recommended dilution
| Application | Dilution |
|---|---|
| Immunofluorescence (IF)/ICC | IF/ICC : 1:250-1:1000 |
| Flow Cytometry (FC) | FC : 0.5 ug per 10^6 cells in 100 ul suspension |
| This reagent has been tested for flow cytometric analysis. It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
| Sample-dependent, Check data in validation data gallery. | |
Product Information
CL488-65069 targets CD8a in IF/ICC, FC applications and shows reactivity with mouse samples.
| Tested Reactivity | mouse |
| Cited Reactivity | mouse |
| Host / Isotype | Rat / IgG2a, kappa |
| Class | Monoclonal |
| Type | Antibody |
| Immunogen |
Spleen cells or thymocyte membranes Predict reactive species |
| Full Name | CD8 antigen, alpha chain |
| GenBank Accession Number | BC030679 |
| Gene Symbol | Cd8a |
| Gene ID (NCBI) | 12525 |
| RRID | AB_2883161 |
| Conjugate | CoraLite® Plus 488 Fluorescent Dye |
| Excitation/Emission Maxima Wavelengths | 493 nm / 522 nm |
| Excitation Laser | Blue laser (488 nm) |
| Form | Liquid |
| Purification Method | Affinity purification |
| UNIPROT ID | P01731 |
| Storage Buffer | PBS with 0.09% sodium azide and 0.5% BSA, pH 7.3. |
| Storage Conditions | Store at 2-8°C. Avoid exposure to light. Stable for one year after shipment. |
Background Information
CD8 is a transmembrane glycoprotein composed of two disulfide-linked chains. It can be present as a homodimer of CD8α or as a heterodimer of CD8α and CD8β (PMID: 3264320; 8253791). CD8 is found on most thymocytes. The majority of class I-restricted T cells express mostly the CD8αβ heterodimer, while CD8αα homodimers alone have been found on some gut intraepithelial T cells, on some T cell receptor (TCR) γδ T cells and on NK cells (PMID: 2111591; 1831127; 8420975). CD8 acts as a co-receptor that binds to MHC class I and participates in cytotoxic T cell activation (PMID: 8499079). During T cell development, CD8 is required for positive selection of CD4-/CD8+ T cells (PMID: 1968084).
Protocols
| Product Specific Protocols | |
|---|---|
| FC protocol for CL Plus 488 CD8a antibody CL488-65069 | Download protocol |
| IF protocol for CL Plus 488 CD8a antibody CL488-65069 | Download protocol |
| Standard Protocols | |
|---|---|
| Click here to view our Standard Protocols |
Publications
What published studies show
The CoraLite® Plus 488 Anti-Mouse CD8a (53-6.7) antibody (catalog CL488-65069) has 5 total citations, all in the immunofluorescence (IF) application. Journals: Journal of Controlled Release, Journal for ImmunoTherapy of Cancer, Cancer Immunology, Immunotherapy, Frontiers in Chemistry, and Molecular and Cellular Endocrinology. The research fields center on cancer immunotherapy, including HCC immunotherapy, PD-L1/anti-tumor immunity, CD8+ T cell responses, and platelet nanovesicle-mediated antitumor effects. Mouse was the cited species.
| Species | Application | Title |
|---|---|---|
J Control Release Self-heating mitochondrion-induced free radical blast for immunogenic cell death stimulation and HCC immunotherapy | ||
J Immunother Cancer THADA drives Golgi residency and upregulation of PD-L1 in cancer cells and provides promising target for immunotherapy. | ||
Cancer Immunol Immunother β-hydroxybutyrate potentiates anti-tumor immunity by modulating cytotoxic CD8(+) T cell responses. | ||
Front Chem Activated platelet membrane nanovesicles recruit neutrophils to exert the antitumor efficiency | ||
Mol Cell Endocrinol Melatonin enhances anti-tumor immunity by targeting macrophages PD-L1 via exosomes derived from gastric cancer cells |



